Biotech Co.* (Symbol) | Pharma Co. (Country) | Product | Disclosed Funding (M) | Terms/Details (Date) |
Abgenix Inc. (ABGX) | Lonza Biologics (UK) | Cell culture production suite | ND | Lonza will make available exclusively to Abgenix, for five years, a cell culture production suite within its facility in Slough, England (1/29) |
AEterna Laboratories Inc. (Canada; AELA) | Grupo Ferrer Internacional SA (Spain) and Medac GmbH (Germany) | Neovastat | C$35 (US$22.9) | The commercialization and distribution agreement calls for double-digit royalties on total net sales, milestone payments and research-expense sharing for anticipated new indications (2/15) |
AlphaRx Inc. (OTC BB:AHRX) | Taiwan PanBiotic Laboratories Co. Ltd. (Taiwan) | AlphaRx's nutraceutical products | ND | AlphaRx signed a letter of intent to enter into a strategic alliance with PanBiotic to commercialize AlphaRx drug discovery products in Taiwan; agreement also calls for AlphaRx to reformulate certain PanBiotic products using AlphaRx's BCD drug delivery technology; AlphaRx granted PanBiotic manufacturing and marketing exclusivity for the reformulated products in exchange for a 35% equity position (2/7) |
Amarillo Biosciences Inc. (OTC BB:AMAR) | Natrol Inc. | Salive | ND | Supply agreement gives Natrol marketing and distribution rights to Salive (12/14) |
Amgen Inc. (AMGN) | Genesis Pharma SA (Greece) | Aranesp | ND | Agreement grants Genesis certain rights to distribute, market and sell Aranesp in Greece and Cyprus (1/18) |
Amgen Inc. (AMGN) | Megapharm Ltd. (Israel) | Aranesp | ND | Agreement is for the marketing and distribution rights for Aranesp in Israel (2/13) |
Antex Biologics Inc. (AMEX:ANX) | O.E.M. Concepts Inc. | Antigen affinity purified moncolonal and polyclonal antibodies | ND | Development and manufacturing agreement of antibodies for commercial use in the detection of food-borne and other enteric pathogens (2/28) |
Atrix Laboratories Inc. (ATRX) | Sanofi-Synthelabo (France) | Leuprogel products | $60 | Marketing deal includes a license fee, research and development support and payments for milestones and royalties; it includes a $15M equity investment in Atrix by Sanofi (1/9) |
BioStratum Inc.* | Kowa Co. (Japan) | Pyridorin | $25 | License agreement granting exclusive rights in Japan, China, Korea and Taiwan to Kowa for the development, manufacturing and marketing of Pyridorin to treat diabetic kidney disease; Kowa will make an up-front payment and pay fees that could reach $25M, as well as royalties on sales (2/6) |
Boston Life Sciences Inc. (BLSI) | Marathon Biopharmaceuticals Inc. | GMP Troponin I | ND | Supply agreement under which Marathon will manufacture GMP Troponin I for BLSI's IND application and its Phase I/II clinical development (1/30) |
Cepheid Inc. (CPHD) | Eurogentec SA (Belgium) | Cepheid Smart Cycler system | ND | Eurogentec will provide sales, marketing and technical support for the Smart Cycler and will serve as the exclusive distributor in Belgium, France, Germany, the Netherlands, Switzerland and the UK (12/14) |
CollaGenX Pharmaceuticals Inc. (CGPI) | PharmaMed Inc. | Periostat | ND | Exclusive Middle East export marketing agreement in which PharmaMed will market the product in the Middle East in return for a fee contingent on sales (1/30) |
Cypress Bioscience Inc. (CYPB) | Fresenius AG (Germany) | Prosorba column | $8 | Restructured partnership agreement in which Fresenius will be responsible for all Prosorba column sales, marketing and clinical efforts worldwide; Cypress will receive an up-front payment of $8M (1/22) |
GeneFormatics Inc.* | Takara Shuzo Co. Ltd. (Japan) | Protein structure/function determination technology | ND | Takara will commercialize the technology in Asia; Takara made an undisclosed investment in GeneFormatics (1/22) |
Genta Inc. (GNTA) | Avecia Ltd. | Genasense | ND | The two-year agreement is for the supply of Genasense for its continued development (12/21) |
Heska Corp. (HSKA) | Novartis Animal Health (unit of Novartis AG; Switzerland) | E-Screen Test | ND | Heska entered a distribution agreement for exclusive rights for Heska's E-Screen Test in Europe (1/3) |
HTS Biosystems Inc.* | Mitsubishi Chemical Corp. (Japan) | HTS's bioanalysis system and surface plasmon resonance technology | ND | Companies entered a license, purchase and distribution agreement in Japan (2/5) |
InKine Pharmaceutical Co. Inc. (INKP) | Unnamed pharmaceutical company | IBStat | ND | The pharmaceutical company will manufacture IBStat, InKine's antispasmodic product (2/1) |
InKine Pharmaceutical Co. Inc. (INKP) | Procter & Gamble Pharmaceuticals | Visicol, approved for bowel cleansing | ND | Copromotion agreement is for 18 months; P&G will receive undisclosed payments and InKine retains all rights and marketing control of Visicol (2/15) |
Ligand Pharmaceuticals Inc. (LGND) | Elan Corp. plc (Ireland) | Ontak, Targretin capsules, Targretin gel, Panretin capsules and Panretin gel | $10 | Exclusive European territorial distribution agreement, which includes an up-front payment to Ligand and possible milestone payments that could total up to $10M (3/1) |
LumiCyte Inc.* | Kratos Analytical Ltd. (UK) | Mass spectrometers | ND | Kratos will supply mass spectrometers to support LumiCyte's protein biochip data aggregation facilities worldwide (2/8) |
Matritech Inc. (NMPS) | Timm Medical Technologies Inc. | NMP22 test | $23 | Distribution agreement for NMP22 test for bladder cancer; deal includes an initial equity investment by Timm in Matritech, marketing fees, milestone payments and increasing minimum test purchases; deal is potentially worth $23M (1/18) |
MGI Pharma Inc. (MOGN) | Helsinn Healthcare SA (Switzerland) | Palonosetron | ND | Companies signed a letter of intent to enter into a North American license and distribution agreement for Helsinn's palonosetron, which is in Phase III trials to prevent chemotherapy-induced nausea and vomiting (2/13) |
NaPro BioTherapeutics Inc. (NPRO) | F.H. Faulding & Co. Ltd. (Australia) | NaPro paclitaxel | $7.5 | Companies entered into a marketing and distribution agreement for NaPro paclitaxel in Europe; Faulding will pay an up-front licensing fee of $7.5M and the firms will share equally in the net sales in the new territories (3/5) |
PPL Therapeutics plc (Scotland; LSE:PTH) | Nihon Nosan Kogyo KK (Japan) | Transgenic production technology | ND | PPL signed an exclusive commercial representation agreement for the Japanese market with Nihon for the sales and marketing of the technology; PPL will pay Nosan a percentage of the contract value (2/2) |
SkyePharma plc (UK; SKYE; LSE:SKP) | Kowa Ltd. (Japan) | NK-104 | ND | Companies signed a contract for the scale-up and manufacturing of Phase III clinical batches of Kowa's new lipid-lowering agent; SkyePharma will provide materials for the European and U.S. clinical trials (2/12) |
SkyePharma plc (UK; SKYE; LSE:SKP) | Meditech Research Ltd. (Australia) | Solaraze | ND | Meditech will commercialize Solaraze in Australia, New Zealand, Malaysia and Singapore; SkyePharma will receive a 15% share of all monies (1/17) |
United Therapeutics Corp. (UTHR) | Orphan Australia Pty. Ltd | UT-15 (Uniprost) | ND | Orphan will be the exclusive distributor of UT-15 in Australia and New Zealand (1/5) |
|
NOTES |
||||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. |
||||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market. |
||||
** Denotes the date the item ran in BioWorld International. |
||||
ND = Not disclosed, reported and/or available |
||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; TSE = Toronto Stock Exchange |
||||